The authors confirm that all data underlying the findings are fully available without restriction. ADNI data were obtained from <https://ida.loni.ucla.edu>. GenADA (dbGaP accession number: phs000219.v1) \[28,29\], eMERGE (dbGaP accession number: phs000234.v1), NIA-LOAD (dbGaP accession number: phs000168.v1), and the Framingham study (dbGaP accession number: phs000007.v16) data were downloaded from dbGaP (<http://www.ncbi.nlm.nih.gov/gap>).

Introduction {#s1}
============

Alzheimer's disease (AD) is a leading cause of dementia and is known to have high heritability (as high as 60--80%) [@pone.0107983-Pedersen1], [@pone.0107983-Gatz1]. Genome-wide association studies (GWAS) have identified several risk genes for AD such as *ABCA7, BIN1, CD33, CD2AP, CLU, CR1, EPHA1, MS4A6A/MS4A4E*, and *PICALM* [@pone.0107983-Harold1]--[@pone.0107983-Seshadri1]. The known risk genes for AD explain only 30% of heritability [@pone.0107983-Bertram1], [@pone.0107983-Sullivan1]. Aside from *APOE* ε4, reported risk genes have low clinical significance because of their small effect sizes [@pone.0107983-Seshadri1]. The common variant hypothesis posited common diseases are attributed to common variants and this hypothesis is base concept for GWAS [@pone.0107983-Reich1], [@pone.0107983-Schork1]. However, similar to other common diseases, the heritability of AD cannot be fully explained by common alleles [@pone.0107983-Manolio1].

There are growing reports regarding rare variants related to complex diseases [@pone.0107983-Asimit1]--[@pone.0107983-Styrkarsdottir1]. Contrary to the common variant hypothesis, variants with low frequency could be primary causes for common diseases, according to the rare variant hypothesis [@pone.0107983-Schork1], [@pone.0107983-Bodmer1]. The rationale of the rare variant hypothesis is that allele variants with low frequencies have a higher probability of functional significance [@pone.0107983-Manolio1]. A large scale exome sequencing study has indicated that 95.7% SNPs with functional importance are rare variants [@pone.0107983-Tennessen1]. Additionally, the number of variants with loss of function showed an inverse correlation with MAF [@pone.0107983-Abecasis1], [@pone.0107983-MacArthur1]. Considering their functional significance, rare variants may have large effect sizes. Recently, rare alleles in *TREM2*, *APP,* and *PLD3* have been reported to have association with AD [@pone.0107983-RoveletLecrux1]--[@pone.0107983-Cruchaga1]. Thus, the identification of more risk or protective rare alleles associated with AD is required.

Although rare alleles are promising targets for genetic association studies of complex diseases, the analyses of rare alleles remains challenging. For example, very large sample sizes are required to detect rare alleles that have modest effect sizes [@pone.0107983-Tennessen1]. Deep sequencing of large samples is too expensive for typical researchers to perform. The mutational loads within the same genes, regions, or pathways can be alternative approach [@pone.0107983-Asimit1], [@pone.0107983-Walsh1]. However, a large number of candidate rare alleles within specific regions are more difficult to obtain and interpret, than genotyping of a few loci.

Improvement of imputation methods has allowed accurate inference of rare alleles [@pone.0107983-Shea1]. According to 1000 genomes study [@pone.0107983-Abecasis1], the mean squared Pearson correlation coefficients (*R* ^2^) between rare SNPs (MAF 0.5%--5%) and imputed dosages were 0.7--0.9 in the European ancestry. Furthermore, mutational loads of rare alleles within genes obtained from imputation can confer high power [@pone.0107983-Magi1]. In this study, we aimed to find risk genes for AD using gene-based analysis of rare alleles deduced from 1000 genomes and publicly available GWAS data.

Materials and Methods {#s2}
=====================

Subjects {#s2a}
--------

We used publicly available GWAS data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), Genetic Alzheimer's Disease Associations (GenADA) study, Electronic Medical Records and Genomics (eMERGE), the National Institute on Aging Late Onset Alzheimer's Disease (NIA-LOAD) family study, and the Framingham study. ADNI data were obtained from <https://ida.loni.ucla.edu>. GenADA (dbGaP accession number: phs000219.v1) [@pone.0107983-Filippini1], [@pone.0107983-Li1], eMERGE (dbGaP accession number: phs000234.v1), NIA-LOAD (dbGaP accession number: phs000168.v1), and the Framingham study (dbGaP accession number: phs000007.v16) data were downloaded from dbGaP (<http://www.ncbi.nlm.nih.gov/gap>). Subjects with European ancestry were included. After genotypic quality control (QC), missing phenotypic data exclusion, and ethnic group selection, 4171 cases and 9358 control were included in this study. Summaries about the studies are shown in [Table 1](#pone-0107983-t001){ref-type="table"}. Additional information for each study were detained in [File S1](#pone.0107983.s001){ref-type="supplementary-material"}. The institutional review board of Ilsan hospital approved our study. Written informed consent was given by participants. In addition patient records were anonymized prior to analysis.

10.1371/journal.pone.0107983.t001

###### Characteristics of studies.

![](pone.0107983.t001){#pone-0107983-t001-1}

  Study                        Genotyping platform              Case/Controlwith genetic data   Case/control after QC[\*](#nt101){ref-type="table-fn"}   No of SNPs after QC   No of imputed SNPs[§](#nt102){ref-type="table-fn"}   No of imputed rare (MAF≤3%) SNPs[§](#nt102){ref-type="table-fn"}
  ---------------- ------------------------------------------- ------------------------------- -------------------------------------------------------- --------------------- ---------------------------------------------------- ------------------------------------------------------------------
  **ADNI**                   Illumina Human610-Quad                        350/169                                     350/169                                 533479                               16242208                                                    8608819
  **ADNI2**               Illumina GenomeStudio v2009.1                    53/125                                       53/125                                 634701                               14860121                                                    7257490
  **GenADA**        Affimetrix Mapping250K_NspMapping250K_Sty              782/806                                     779/803                                 432763                               14441395                                                    6863818
  **eMERGE**              Illumina Human660W-Quad_v1_A                    676/1843                                     632/1843                                535401                               16190257                                                    8572925
  **NIA-LOAD**             Illumina Human610-Quad_v1_B                    2244/2320                                   2098/2095                                542080                               19568275                                                    11943583
  **Framingham**    Affimetrix Mapping250K_NspMapping250K_Sty             314/4711                                     259/4323                                371114                               16510848                                                    8908801

\* In addition to genotyping QC, we selected only European ancestry without missing information on age and sex.

SNPs with INFO≥0.4.

Genotypic QC and imputation {#s2b}
---------------------------

We excluded alleles with low (\<1%) MAF, low (\<95%) call rate, and deviation of Hardy-Weinberg Equilibrium (*P*\<10^--6^). The subjects with low (\<95%) call rates, too high autosomal heterozygosity (false discovery rate, FDR\<1%) and too high relatedness (identical-by-state, IBS\>0.95) were excluded. For genotypic QC, we used the GenABEL package, v 1.69 [@pone.0107983-Aulchenko1].

After estimating haplotypes using SHAPEIT, v 1.0 [@pone.0107983-Delaneau1], imputation with multi-population reference panels of 1000 genomes (phase I, release Mar 2012) was executed using IMPUTE2, v 2.2 with default parameters [@pone.0107983-Howie1], [@pone.0107983-Howie2]. We discarded imputated SNPs with INFO\<0.4. The dosage data of imputation were used for further analyses. The dosage means the expected genotype score [@pone.0107983-Zheng1].

Statistical analyses {#s2c}
--------------------

In the association study, we adjusted for age, sex, years of education, and significant principle components (PCs) of the genetic stratification ([File S1](#pone.0107983.s001){ref-type="supplementary-material"}). For consistency across studies, years of education were categorized as follows: **1**, ≤ 4; **2**, 4\< and ≤10; **3**, 11\< and ≤ 15; **4**, \>15 years according to the established methods of stratifications in the GenADA study. We imputed missing years of education to a mean value. The years of education was regarded as a continuous variable.

We performed a weighted, *Z* score based, fixed-effects, meta-analysis using METAL [@pone.0107983-Willer1]. The effect sample size (*N~E~*) for meta-analysis is given in terms of numbers of AD (*N~AD~*) and of controls (*N~C~*), as follows [@pone.0107983-Willer1]:

The forest plot was drawn using 'rmeta' R package.

*APOE* is the strongest risk gene among the known risk genes for AD. In several genome-wide association studies for AD [@pone.0107983-Harold1], the top ranked genes could show false associations with AD, because they are within same LD block of *APOE* ε4. In addition, the pathogenesis of AD patients might be different between carriers and noncarriers of *APOE* ε4 [@pone.0107983-Rhinn1]. Therefore, we examined the dependency on *APOE* ε4 genotype status by two ways. First, the results were compared after adjustment for *APOE* ε4 genotype status -- the number of *APOE* ε4 allele in each individual. eMERGE and the Framingham study did not include data on *APOE* ε4 genotype status. Therefore, we used imputed dosages of *APOE* ε4 for these two studies (Table S1 in [File S1](#pone.0107983.s001){ref-type="supplementary-material"}). Second, the collinearity between selected genes and *APOE* ε4 genotype status was examined.

Gene-based rare allele analysis {#s2d}
-------------------------------

In this study, gene-based rare allele analysis means accumulations of rare alleles within the same coding region implemented in GRANVIL [@pone.0107983-Magi1]. The definition of gene boundaries was based on the UCSC genome browser (build 37). The Framingham study showed inflated type I error and skewed results (Figures S1 and S2 in [File S1](#pone.0107983.s001){ref-type="supplementary-material"}). Therefore, we need to adjust for genetic stratification of the Framingham study using another algorithm implemented in GenABEL v1.69 and ProbABEL v0.30 [@pone.0107983-Aulchenko1], [@pone.0107983-Aulchenko2] (Figure S2 in [File S1](#pone.0107983.s001){ref-type="supplementary-material"}). For gene-based analysis of the Framingham study, we need to make computer program for ourselves. We made a dosage of a gene (*D*) similar to an allele's dosage in the Framingham study, as follows [@pone.0107983-Magi1].

Where *Gi* is a dosage of the *i*th SNP and *n* is a number of rare alleles within a gene that were used in the analysis.

Analyses proceeded in two steps. The overall study scheme is shown in [Figure 1](#pone-0107983-g001){ref-type="fig"}. We performed the first meta-analysis to select genes with genome-wide significance. The genome-wide significance was defined as significance of *P*\<1.8×10^−6^ (0.05/number of genes in human genome in UCSC genome browser (build 37) = 0.05/28517). However, there are three shortcomings in the gene-based rare allele analysis using imputation. First, it is difficult to interpret if there are a lot of rare alleles in a gene. Second, by pooling risk and protective alleles, power can be decreased. However, considering such directions before selecting candidate genes, overinflation of type I error can be problematic. Third the accuracy of imputation can be decreased in rare alleles with very low MAF. We performed confirmatory analysis (the second meta-analysis) with selected SNPs We did confirmatory analysis, according to two reasons. First, if we could test genetic risk factors with a small number of SNPs, it would be more convenient for genotyping and interpretation. Therefore, we selected several risk SNPs in the finally selected gene according to meta *P* and meta *Z* (*P*\<0.05 and Z\>0) after performing classical SNP based GWAS and meta-analysis. Second, we excluded rare variants with MAF\<0.5%, because the imputation accuracy decreases in very low MAF [@pone.0107983-Abecasis1].

![The overall scheme of this study.](pone.0107983.g001){#pone-0107983-g001}

Results {#s3}
=======

The first meta-analysis {#s3a}
-----------------------

In the meta-analysis, *ZNF628* had genome-wide significance (meta *P* = 5.3×10^--7^ \[OR 1.5, 95% CI 1.3--1.8\]) ([Table 2](#pone-0107983-t002){ref-type="table"} and [Figure 2A](#pone-0107983-g002){ref-type="fig"}). SNPs in *ZNF628* used in this study are summarized in Table S2 in [File S1](#pone.0107983.s001){ref-type="supplementary-material"}. In addition, *APOE* had also genome-wide significance (meta *P* = 1.4×10^--6^). Other genes with high significances, but not with genome-wide significance were *TOMM40, MMP1, NAPRT1, TREM2,* and *CBLB*.

![Forest plots showing the association of *ZNF628* with AD.\
Results are (A) with all rare SNPs (the first meta-analysis) and (B) with only selected risk SNPs (the second meta-analysis). The weight of each study was calculated by 4/(1/*N~AD~*+1/*N~C~*), where *N~AD~* and *N~C~* are numbers of AD and controls, respectively [@pone.0107983-Willer1].](pone.0107983.g002){#pone-0107983-g002}

10.1371/journal.pone.0107983.t002

###### The highly ranked seven genes in the first meta-analyses.

![](pone.0107983.t002){#pone-0107983-t002-2}

  Gene            CHR     Start     not adjusted for *APOE* ε4   adjusted for *APOE* ε4                  
  -------------- ----- ----------- ---------------------------- ------------------------ --------- ----- -------------
  ***ZNF628***    19    55987698               5.0                    5.3×10^--7^         ++++++    5.2   1.3×10^--7^
  ***APOE***      19    45409038               4.8                    1.4×10^--6^         +?+++--   2.3      0.023
  ***TOMM40***    19    45394477               4.1                    4.0×10^--5^         +--++++   2.3      0.018
  ***MMP1***      11    102654407              4.0                    6.6×10^--5^         --++++    4.1   4.0×10^--5^
  ***NAPRT1***     8    144656956              3.9                    7.8×10^--5^         ++++++    4.5   8.0×10^--6^
  ***TREM2***      6    41126245               3.8                    1.2×10^--4^         ++++++    4.6   3.7×10^--6^
  ***CBLB***       3    105438891              3.8                    1.5×10^--4^         ++++++    3.2     0.0015

We show the highly ranked genes (meta *P*\<2.0×10^--4^) in the first meta-analysis in this table.

Protein names: zinc finger protein 628, ZNF628; apolipoprotein E, APOE; translocase of outer mitochondrial membrane 40, TOMM40; matrix metallopeptidase 1, MMP1; nicotinate phosphoribosyltransferase domain containing 1, NAPRT1; triggering receptor expressed on myeloid cells 2, TREM2; Cbl proto-oncogene B, E3 ubiquitin protein ligase, CBLB.

\* Larger absolute *Z* score represents smaller *P* and the direction of the *Z* score represents the direction of risk [@pone.0107983-Willer1].

The signs mean those of the *Z* score of each study. The question mark represents missing data in the study because of low INFO or high MAF. The order of the signs is ADNI, ADNI2, GenADA, eMERGE, NIA-LOAD, and Framingham study.

Dependency on *APOE* ε4 genotype status {#s3b}
---------------------------------------

We examined the dependencies of the selected genes by adjusting for *APOE* ε4 ([Table 2](#pone-0107983-t002){ref-type="table"}). The significance of *ZNF628* was remained, even after adjustment. However, the significance of *APOE* decreased after adjustment for *APOE* ε4 (after adjustment, *P* value of *APOE* increased to 0.023).

Additionally, the collinearity between *ZNF628* and *APOE* ε4 genotype status were examined based on the variance inflation factor (VIF, Table S3 in [File S1](#pone.0107983.s001){ref-type="supplementary-material"}). The VIFs of all studies were approximately 1.

Meta-analysis with selected risk SNPs (the confirmatory second analysis) {#s3c}
------------------------------------------------------------------------

For a more applicable clinical approach, we identified significant risk SNPs by meta *P* and meta *Z* scores. Furthermore, considering the imputation accuracy [@pone.0107983-Abecasis1], we selected SNPs with 0.5% ≤ MAF≤3%. Two risk SNPs (dbSNP ID: rs112407198 and rs73057174) selected within *ZNF628* were synonymous SNPs ([Figure 3](#pone-0107983-g003){ref-type="fig"}). As shown in [Figure 2B](#pone-0107983-g002){ref-type="fig"} and [Table 3](#pone-0107983-t003){ref-type="table"}, gene-based rare allele analysis using only selected SNPs had genome-wide significance with moderately high effect size (meta *P* = 3.7×10^--7^ \[OR 1.7, 95% CI 1.4--2.0\]).

![Schematic representation of *ZNF628* with locations of SNPs used in gene-based rare allele analysis in this study.\
*ZNF628* is a protein 1059 amino acids long. We briefly showed the domains (boxes) and the locations of SNPs (arrows) in a schematic linear structure of *ZNF628*. Blue boxes denote C2H2-type zinc finger domains. dbSNP ID can be found in Table S2 in [File S1](#pone.0107983.s001){ref-type="supplementary-material"}. SNPs within red boxes were used in the second analysis.](pone.0107983.g003){#pone-0107983-g003}

10.1371/journal.pone.0107983.t003

###### Results of the second meta-analysis (confirmatory analysis).

![](pone.0107983.t003){#pone-0107983-t003-3}

                    rs112407198 (position: 19∶55995401)   rs73057174 (position: 19∶55995710)   Gene-based                                                                                                        
  ---------------- ------------------------------------- ------------------------------------ ------------ -------- ------- -------- ------- ------ -------- ------------- --------- ------------- ------------- -------------
  **ADNI**                         0.011                                 0.78                     0.29       0.70    0.09     0.91    0.029   0.91    0.08       0.85        0.39        0.40          0.73          0.43
  **ADNI2**                        0.009                                 0.82                    --8.7       0.79    0.50     0.87    0.031   0.95   --0.30      0.63       --0.083      0.90          0.74          0.55
  **GenADA**                       0.011                                 0.47                     1.99      0.0052   1.93    0.0079   0.022   0.67    0.52       0.11        0.59        0.093        0.0045        0.0049
  **eMERGE**                       0.012                                 0.72                     0.16       0.65    0.11     0.75    0.022   0.90    0.32       0.15        0.26        0.26          0.14          0.26
  **NIA**                          0.013                                 0.74                     0.24       0.39    0.079    0.80    0.024   0.90    0.46       0.011       0.62       0.0015        0.0084        0.0042
  **Framingham**                   0.011                                 0.41                     1.31      0.0079   1.34    0.0066   0.019   0.55    1.35      0.00026      1.34       0.00029     1.0×10^--5^   9.7×10^--6^
  **Meta**                                                                                                  0.0043           0.019                            2.8×10^--5^             2.7×10^--6^   3.7×10^--7^   2.8×10^--7^

Key: MAF, minor allele frequency; INFO, imputation quality score made by IMPUTE2.

Gene-based rare allele analyses for the genes known to be associated with AD {#s3d}
----------------------------------------------------------------------------

Interestingly, rare alleles in *APOE* and *TREM2* showed significantly high association with AD ([Table 2](#pone-0107983-t002){ref-type="table"}). Thus, we tested rare alleles of other known genes associated with AD. The most highly ranked nine genes in the AlzGene database [@pone.0107983-Bertram2] (*ABCA7, PICALM, CLU, MS4A6A/MS4AE, CD33, BIN1, CR1, and CD2AP*) were selected for the test. Based on the meta-analysis, only *BIN1* had significance (meta *P* = 0.046), but did not reach to genome-wide significance level ([Table 4](#pone-0107983-t004){ref-type="table"}).

10.1371/journal.pone.0107983.t004

###### Results of gene-based rare allele analysis top ranking genes in the AlzGene database.

![](pone.0107983.t004){#pone-0107983-t004-4}

  Gene            CHR     start     Meta *Z*   Meta *P*   Directions[\*](#nt109){ref-type="table-fn"}
  -------------- ----- ----------- ---------- ---------- ---------------------------------------------
  ***ABCA7***     19     1040101      0.2       0.8539                      +++--+
  ***PICALM***    11    85668485     --0.4      0.7068                     --?+--+--
  ***CLU***        8    27454450     --1.1      0.2554                      --++--
  ***MS4A6A***    11    59939080      0.5       0.6377                     --+--+--+
  ***CD33***      19    51728334     --0.4      0.7185                      --++--
  ***BIN1***       2    127805606     2.0       0.0460                      ++++--
  ***MS4A4E***    11    59980567      0.5       0.6377                     --+--+--+
  ***CR1***        1    207669472     0.7       0.5050                     ++--+--+
  ***CD2AP***      6    47445524     --1.1      0.2593                      --+--+

Protein names: ATP-binding cassette, sub-family A, ABCA7; phosphatidylinositol binding clathrin assembly protein, PICALM; clusterin, CLU; membrane-spanning 4-domains, subfamily A, member 6A, MS4A6A; CD33 molecule, CD33; bridging integrator 1, BIN1; putative membrane-spanning 4-domains subfamily A member 4E, MS4A4E; complement component (3b/4b) receptor 1, CR1; CD2-associated protein, CD2AP.

\* The signs represent those of the *Z* score of each study. The question mark represents missing data in the study because of low INFO or high MAF. The order of the signs is ADNI, ADNI2, GenADA, eMERGE, NIA, and Framingham study.

Discussion {#s4}
==========

We performed meta-analysis with publicly available genetic studies of AD with imputed rare (MAF≤3%) alleles. *ZNF628* was identified to have significant association with AD. Additionally, our rare allele analysis revealed the significant association of *APOE* and *TREM2* with AD, which suggested that our results were valid and that these genes require further study [@pone.0107983-Jonsson2], [@pone.0107983-Guerreiro1].

*ZNF628* is a C2H2-zinc finger protein, a type of transcription factors [@pone.0107983-Chen1] consisting of three exons. C2H2-type zinc finger proteins are known to be essential for normal growth and development [@pone.0107983-Chen1]. *ZNF628* is found in mammals, but not Zebra fish or C. elegans [@pone.0107983-Chen1]. *ZNF628* is evenly expressed in various tissues including brain [@pone.0107983-Wu1], [@pone.0107983-Derrien1]. *ZNF628* is conserved among mammals and seems to be functionally important [@pone.0107983-Chen1]. The possible DNA binding site is the sequence motif -- C/GA/TA/TGGTTGGTTGC [@pone.0107983-Chen1]. As this time, the target proteins and related human disorders associated with *ZNF628* have not been reported. It is possible that the rare alleles in *ZNF628* change the expression levels of certain proteins related to AD pathogenesis.

In the selected allele analysis of *ZNF628* (the second confirmatory analysis), *P* and *Z* values of two SNPs (rs112407198 and rs73057174) reached the criteria of *P*\<0.05 and *Z*\>0. These SNPs are located outside the C2H2-type zinc finger domains and synonymous SNPs ([Figure 3](#pone-0107983-g003){ref-type="fig"}). The synonymous mutations are known to change the protein expression level and conformation [@pone.0107983-Sauna1] by affecting mRNA structure [@pone.0107983-Nackley1] or changing the time of cotranslational folding [@pone.0107983-KimchiSarfaty1]. The altered expression levels or structure of *ZNF628* could affect the expression level of other proteins.

There were no dependencies between *ZNF628* and *APOE* ε4 genotype status. *ZNF628* is separated from *APOE* by more than 10^8^bp, although they are both located on chromosome 19. Therefore, *ZNF628* is not included in same LD block with *APOE* ε4. *ZNF628* did not lose its significance in meta-analysis even after adjustment for *APOE* ε4 genotype status. Therefore, *ZNF628* appears to be related with AD independently from *APOE* ε4. In contrast, the significance of *APOE* was affected by *APOE* ε4. The association of the rare alleles in *APOE* with AD was highly significant (*P* = 1.4×10^--6^) with AD, although this significance disappeared after adjusting for *APOE* ε4. This suggested that rare alleles in the same LD block with *APOE* ε4 conferred significant association with AD.

Other risk genes that have been found in GWAS targeting common alleles were not replicated in our gene-based rare allele analysis. Only *TREM2*, which has been identified in previous studies targeting rare alleles, showed high significance levels [@pone.0107983-Jonsson2], [@pone.0107983-Guerreiro1]. Common alleles with small effect sizes have been explained by synthetic association of rare alleles [@pone.0107983-Dickson1], [@pone.0107983-Cirulli1]. Recently, however, this hypothesis was not confirmed in a large-scale study of seven common immune diseases [@pone.0107983-Hunt1]. Similarly, we could not show association of rare alleles within the known genes with AD.

There are several limitations in this study. First, a replication study with real genotyping is required. However, 1000 genomes-based imputations can enable us to find refined and novel signals [@pone.0107983-Huang1]. Furthermore, the sample size and power can be increased by imputation [@pone.0107983-deBakker1] and meta-analysis [@pone.0107983-Skol1]. Our gene-based rare variant analysis by imputation have comparable high power with re-sequencing analysis, especially with a large number of sample size [@pone.0107983-Magi1]. Second, rare alleles analysis of *ZNF628* of this study was performed in White populations. Although this result should be replicated in different populations, it is difficult to identify. The two important selected SNPs of our study, rs11247198 and rs73057174, have not been reported in Asian populations, whereas higher MAF has been identified in Black populations (especially in the Bushmen). Third, current methods of rare allele analysis still have problems and need more powerful and consistent methods [@pone.0107983-Bansal1]. The simulated studies using 20 different tools did not generate consistent results [@pone.0107983-Bansal2]. Therefore, simulation studies to identify methods that generate the optimal results are required [@pone.0107983-Bansal1]. Additionally, the directions of SNPs for related diseases are not usually considered [@pone.0107983-Bansal1]. Lastly, the SNPs in introns could not be considered because of limited our computational resources.

In conclusion, we observed a noble association between *ZNF628* and AD. Considering the biological role of the *ZNF628* protein, it may contribute to AD by regulating various AD-related proteins expressions. Functional studies to elucidate its contribution to AD pathogenesis are required. Additionally, further studies addressing different populations should be replicated to assess the value of the *ZNF628* rare allele as a genetic biomarker of AD.

Supporting Information {#s5}
======================

###### 

**Supplement text, tables, and figures.**

(DOCX)

###### 

Click here for additional data file.

We used the supercomputing resource of the Korea Institute of Science and Technology Information (KISTI).

ADNI got a grant from the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering. Additionally, ADNI was supported by the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. ADNI clinical sites in Canada got funds from the Canadian Institutes of Health Research. The Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org)) facilitated private sector contributions. The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, Rev October 16, 2012 San Diego. The Laboratory for Neuro Imaging at the University of California, Los Angeles disseminated ADNI data. ADNI was also supported by NIH grants (P30 AG010129 and K01 AG030514). The genotypic and associated phenotypic data used in the study, "Multi-Site Collaborative Study for Genotype-Phenotype Associations in Alzheimer's Disease (GenADA)" were provided by the GlaxoSmithKline, R & D Limited. Alzheimer's Disease Patient Registry (ADPR) and Adult Changes in Thought (ACT) study was supported by a U01 from the National Institute on Aging (Eric B. Larson, PI, U01AG006781). The 3M Corporation gave a gift and it was used to expand the ACT cohort. DNA aliquots sufficient for GWAS from ADPR Probable AD cases, who had been enrolled in Genetic Differences in Alzheimer's Cases and Controls (Walter Kukull, PI, R01 AG007584) and obtained under that grant, were made available to eMERGE without charge. Genotyping, which was performed at Johns Hopkins University, was supported by the NIH (U01HG004438). GWAS were supported through a Cooperative Agreement from the National Human Genome Research Institute, U01HG004610 (Eric B. Larson, PI). The eMERGE Administrative Coordinating Center (U01HG004603) and the National Center for Biotechnology Information (NCBI) helped phenotype harmonization and genotype data cleaning. The "Genetic Consortium for Late Onset Alzheimer's Disease" was supported by the Division of Neuroscience, NIA. In NIA-LOAD study, Genetic Consortium for Late Onset Alzheimer's Disease helped phenotype harmonization and genotype cleaning, as well as with general study coordination. The Genetic Consortium for Late Onset Alzheimer's Disease includes a GWAS funded as part of the Division of Neuroscience, NIA. The Framingham Heart Study is performed and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195). Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL-64278. The Framingham Dementia Mild Plus Incidence dataset was supported by NIH/NIA grants R01 AG08122 and R01 AG033193. The Framingham Dementia Moderate Plus Incidence dataset was supported by NIH/NIA grants R01 AG08122 and R01 AG033193.

However, we did not receive the commercial funds that are shown in this section. Although the data in our study can be publicly available, it was mandatory to show the funding sources for the studies. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

This manuscript was not written in collaboration with investigators of the Framingham Heart Study and does not necessarily reflect the opinions or views of the Framingham Heart Study, Boston University, or NHLBI.

Some of data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.

A complete listing of ADNI investigators can be found at:<http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: JHK SAP. Performed the experiments: JHK SAP. Analyzed the data: JHK HSL J-HL SAP. Contributed reagents/materials/analysis tools: JHK J-HL SAP. Contributed to the writing of the manuscript: JHK PS HSL J-HL JHL SAP. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: JHK PS HSL J-HL JHL SAP.
